Two authors (JC and JW) extracted relevant data independently, and a third author (HX) was consulted to resolve discrepancies when necessary. Viewpoints held by 2 investigators would be the final decision. Essential clinical characteristics extracted from the enrolled studies including: names of the researches, numbers of patients included, median age, gender, racial distribution, ECOG performance status, smoking history, brain metastasis status, liver metastasis status, and median sum of longest diameter of target lesions. During the data exaction of included studies, we checked and reviewed the clinical trials registries on www.clinicaltrials.gov. The primary outcomes evaluated in the present network meta-analysis were PFS (randomization to progression of any causes or death regardless of any causes) and OS (randomization to death regardless of any causes). Secondary endpoints items consisted of ORR (patients evaluated as complete response (CR) or partial response (PR) according to the criteria of RECIST version 1.1), disease control rate (DCR) (patients evaluated as CR or PR or stable disease), AEs lead to treatment discontinuation, AEs at high grade (≥ grade 3), fatal adverse events (FAEs), immune-related AEs, and specific AEs including hypothyroidism, hyperthyroidism, rash, pneumonitis, hepatitis, and colitis.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.